# NGN Capital

NGN Capital is a Private Equity based in Stamford, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Stamford, United States
- **Region:** North America
- **Address:** Stamford, CT, United States
- **Founded:** 2003
- **Assets under management:** $450M
- **Website:** www.ngncapital.com
- **LinkedIn:** https://www.linkedin.com/company/ngn-capital

## Regulatory record

- **CRD number:** 162938
- **SEC file number:** 802-75933
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/162938

## About

NGN Capital is a healthcare-focused venture capital firm with offices in New York and Heidelberg, Germany. The firm manages a series of healthcare venture funds totaling approximately $450 million. Its investments span healthcare services, medical devices, and biotech.

## Sectors

- Healthcare Services
- Digital Health
- Medical Devices
- Biotech

## Offices

- Heidelberg, Germany

## People

- Kenneth S. Abramowitz — Managing General Partner
- John R. Costantino — Managing General Partner
- Peter Johann — Managing General Partner

## Questions

### Who makes investment decisions at NGN Capital?

Three managing general partners — Kenneth Abramowitz, John Costantino, and Peter Johann — lead the investment committee. Abramowitz brings Wall Street and Carlyle healthcare buyout experience; Costantino contributes tax, operating, and public-company board expertise; Johann supplies global pharma corporate-development knowledge from Boehringer Ingelheim and Roche. Venture partner Kenneth Gorelick and senior advisor William Gedale provide additional clinical and venture-governance input.

### How does NGN Capital source healthcare deals?

The firm leverages a transatlantic network built by Abramowitz during his 23 years as a top-ranked equity analyst and Johann during his tenure at Boehringer Ingelheim and Roche. Gedale’s long-standing ties to research institutions — he arranged funding for Scripps Research Institute and the Neuroscience Institute of La Jolla — provide a university-origination channel that complements the partners’ industry relationships across US and European biotech hubs.

### What investment stages does NGN Capital typically target?

NGN invests across the venture lifecycle, from early-stage and start-up rounds through expansion, late-stage growth, PIPEs, and pre-IPO positions. The firm’s $450 million fund series is structured to support both initial clinical validation and later regulatory- or commercial-stage milestones in therapeutics, medical devices, and diagnostics.

### Does NGN Capital operate solely in the United States?

No. NGN maintains offices in Stamford, Connecticut and Heidelberg, Germany, and runs parallel US and German fund vehicles. Peter Johann’s European pharma background and the German office give the firm the ability to diligence and syndicate deals on both sides of the Atlantic.

### How is NGN Capital connected to Carlyle Group?

Kenneth Abramowitz joined NGN from Carlyle, where he was a managing director focused on US healthcare buyouts from 2001 to 2003 and later a senior advisor. NGN was initially conceived as a dedicated healthcare venture vehicle during Abramowitz’s Carlyle tenure, though it now operates as an independent firm with no ongoing Carlyle affiliation.

## Related profiles

- [NGM Group](https://altss.com/profile/ngm-group)
- [NGP](https://altss.com/profile/ngp)

---

Last updated: 2026-07-10T08:12:01.000Z

Canonical page: https://altss.com/profile/ngn-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology